Predictive Technology Group Awarded Patent for Spinal Deformity Treatment

Predictive Technology Group Inc., a life sciences technology holding company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a fundamental patent application that covers the practice of administering any spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.
 
“We are pleased to see this latest allowance that supports PRED’s novel approach to diagnosing spinal disorders and syndromes, “said Mike Schramm, PRED’s director of intellectual property. “This allowed U.S. patent application supports the commercial use of both our diagnostic and next-generation companion treatment products.”

The allowance of this new application is a significant milestone for Predictive Technology Group, according to the company. The patent establishes the foundation of key intellectual property covering any treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker. This newly allowed application is additive to previously announced patents. Furthermore, the company has additional U.S. and international patent applications pending and will pursue such applications with the objective of receiving additional issued patents in additional disease states.

“We are gratified to see this latest application allowance, which covers the core technology underlying the company’s molecular diagnostic test” said Bradley Robinson, president and CEO of Predictive Technology Group. “Furthermore, this fundamental patent covers not only spinal applications of our technology, but establishes a precedent for the other patent applications that have been submitted on the company’s portfolio of next-generation diagnostic and companion treatment products.”
 
Predictive Technology Group, through its wholly owned subsidiaries, develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases. The firm is based in Salt Lake City, Utah.